Company history

1997

New and improved production method for glucosamine developed by Øyvind Brekke at the University NTNU in Norway (the Brekke-method).

2002 

Glucomed AS established as holding company for the development, production and sales of glucosamine ingredient and finished products. 

2003

Co-operation established with the Norwegian pharmaceutical company Weifa AS for the development of a glucosamine pharmaceutical product. Co-operation established with Hydro Organic for further development of the Brekke-method. External investors invited in as shareholders. All placements fully subscribed.

2004

Application for Marketing Authorization for the finished product Glucomed filed in Sweden. First marketing and distribution agreement for Glucomed signed with Meda AB. Change of name to Navamedic ASA

2005

Marketing Authorization received for Glucomed in Sweden. MRP application launched. Glucomed launched in Sweden. 

2006

Approval of Glucomed in 24 further EU/EEA countries through the decision in the EU Commission. Started construction of chitin plant adjasent to Nergård Reker at Senjahopen, Troms. Glucomed launched on Iceland. The Navamedic share listed on Oslo Stock Exchange.

2007

Acquisition of Vitaflo Scandinavia AB. Glucomed launched in Germany, United Kingdom, Denmark, the Czech Republic, the Slovak Republic and Austria. 

2008

Integration of Vitaflo in the Group and sale of the Glucomed business area. 

2009

Restruction with new management.

2010

Exclusive distribution agreement with Aspen Pharma  

2011

Introducing the first generic products